Zymeworks Inc

Zymeworks Inc. is a biopharmaceutical company. It engages in the discovery, development, and commercialization of multifunctional biotherapeutics, initially focused on the treatment of cancer. The company is headquartered in Middletown, DE.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Zymeworks reports improved Q1 performance and focuses on pipeline progress

Zymeworks reported improved revenue and decreased net loss. The company is optimistic about the progress in their pipeline, particularly with zanidatamab. They are focused on Phase 2 studies and potential partnerships for their products. Zymeworks is also exploring potential monetization of future milestones and royalties.

ZYME reports improved Q2 performance and strategic leadership additions

ZYME reported improved financial performance, strategic additions to its leadership, and a focus on efficient development. However, challenges exist in financial impacts and areas of scrutiny from analysts. The company sees opportunities in sharing ongoing data and results at conferences and remains optimistic about its position.

Zymeworks reports reduced net loss and introduces potential first-in-class ADC molecule

Zymeworks has made significant progress in reducing net loss and increasing revenue, while also introducing a potential first-in-class ADC molecule for the treatment of HCC. The company's financial position is strong, with a comfortable cash runway and opportunities to advance its pipeline. However, managing operational costs and maintaining a cost-effective infrastructure will be crucial for sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks Inc (ZYME) delivered earnings and revenue surprises of 28.89% and 6.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc (ZYME) Reports Q1 Loss, Tops Revenue Estimates

Aurinia Pharmaceuticals

Kodiak Sciences Inc

These three developmental-stage pharma stocks are attracting some of the smartest investors right now.

Billionaires Are Gobbling Up These 3 Healthcare Stocks

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -97.62% and -79.64%, respectively, for the quarter ended December 2019.

Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates

Xenon Pharmaceuticals

These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.

3 Canadian Biotechs to Consider Buying Today

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -1.45% and 1.22%, respectively, for the quarter ended September 2019.

Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: Zymeworks Inc. (ZYME) Q3 Earnings Expected to Decline

MacroGenics

Merus

Seagen

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

4 Stocks Battling Breast Cancer

Canadian biotech Zymeworks Inc. (NYSE: ZYME) over the weekend announced more data from an ongoing clinical trial of a drug to treat HER2-type cancers and announced a Phase 2 trial in another cancer drug, leading to a more bullish stance on the company’s stock from Raymond James.

Raymond James Upgrades Zymeworks, Says Encouraging Cancer Drug Is 'Born to Run'

Amgen

Immunomedics

Doctors, researchers, and pharmaceutical experts will converge upon Barcelona to share the latest results in cancer research. Here is a run-down on three to watch.

Cancer Results to Watch at This Weekend’s European Society of Medical Oncology Congress

As of late, it has definitely been a great time to be an investor in Zymeworks.

Zymeworks' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Zymeworks.

Will Zymeworks Continue to Surge Higher?

Shares have nearly doubled since my initial recommendation to buy the dip in February of last year.

Zymeworks: Leader In Bispecifics Space Makes Substantial Headway

News for Zymeworks Inc Stock (ZYME)